P53 Mutation and LOH at Chromosome 9 in Urothelial Carcinoma

被引:0
作者
Beothe, Tamas [2 ,3 ]
Nagy, Anetta [2 ]
Farkas, Laszlo [3 ]
Kovacs, Gyula [1 ,2 ]
机构
[1] Univ Pecs, Sch Med, Dept Lab Med, H-7624 Pecs, Hungary
[2] Univ Heidelberg, Fac Med, Heidelberg, Germany
[3] Univ Pecs, Sch Med, Dept Urol, H-7624 Pecs, Hungary
关键词
Urothelial carcinoma; chromosome 17p LOH; p53; mutation; chromosome; 9; LOH; developmental pathway; TRANSITIONAL-CELL CARCINOMA; TUMOR-SUPPRESSOR GENE; BLADDER-CANCER; IDENTIFIES PTPRD; URINARY-BLADDER; HYPERMETHYLATION; PROGRESSION; KINASE; GLIOBLASTOMA; ASSOCIATION;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Mutation of the p.5.3 gene has been implicated in the development of carcinoma in situ (CIS) to invasive solid urothelial carcinomas (UC) whereas loss of heterozygosity (LOH) at chromosome 9 has been suggested to plag part in the development of papillary UCs. Patients and Methods: The p53 mutation and LOH at chromosomes 17p13.1 and 9 were analysed in 120 UCs. Tumor and matched normal DNA were used for microsatellite allelotyping of chromosome 17p and the entire chromosome 9. Results: LOH at 17p13.1 was found in each grade and stage of the UCs, but mutation of the p53 occurred only in the highly malignant G3 tumors including papillary pT1G3 UCs. LOH were found at one or more of the seven tumor suppressor gene loci along chromosome 9 in all but two of the UCs with p53 mutation. Conclusion: Mutation of the p53 gene is not a pathway correlated genetic change, but is associated with the increased cell proliferation of G3 UCs.
引用
收藏
页码:523 / 527
页数:5
相关论文
共 29 条
[1]   Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma [J].
Akagi, Tadayuki ;
Ito, Tetsuo ;
Kato, Motohiro ;
Jin, Zhe ;
Chen, Yulan ;
Kan, Takatsugu ;
Yamamoto, Go ;
Olaru, Alexandru ;
Kawamata, Norihiko ;
Boult, Jessica ;
Soukiasian, Harimik J. ;
Miller, Carl W. ;
Ogawa, Seishi ;
Meltzer, Stephen J. ;
Koeffler, H. Phillip .
INTERNATIONAL JOURNAL OF CANCER, 2009, 125 (10) :2349-2359
[2]   Pathways of urothelial cancer progression suggested by Bayesian network analysis of allelotyping data [J].
Bulashevska, S ;
Szakacs, O ;
Brors, B ;
Eils, R ;
Kovacs, G .
INTERNATIONAL JOURNAL OF CANCER, 2004, 110 (06) :850-856
[3]   Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma [J].
Catto, JWF ;
Azzouzi, AR ;
Rehman, I ;
Feeley, KM ;
Cross, SS ;
Amira, N ;
Fromont, G ;
Sibony, M ;
Cussenot, O ;
Meuth, M ;
Hamdy, FC .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (13) :2903-2910
[4]  
Chan MWY, 2002, CLIN CANCER RES, V8, P464
[5]   CRYSTAL-STRUCTURE OF A P53 TUMOR-SUPPRESSOR DNA COMPLEX - UNDERSTANDING TUMORIGENIC MUTATIONS [J].
CHO, YJ ;
GORINA, S ;
JEFFREY, PD ;
PAVLETICH, NP .
SCIENCE, 1994, 265 (5170) :346-355
[6]  
Chow NH, 2000, INT J CANCER, V89, P514, DOI 10.1002/1097-0215(20001120)89:6<514::AID-IJC8>3.3.CO
[7]  
2-8
[8]   IDENTIFICATION OF A NOVEL SERINE THREONINE KINASE AND A NOVEL 15-KD PROTEIN AS POTENTIAL MEDIATORS OF THE GAMMA-INTERFERON-INDUCED CELL-DEATH [J].
DEISS, LP ;
FEINSTEIN, E ;
BERISSI, H ;
COHEN, O ;
KIMCHI, A .
GENES & DEVELOPMENT, 1995, 9 (01) :15-30
[9]   High Resolution ArrayCGH and Expression Profiling Identifies PTPRD and PCDH17/PCH68 as Tumor Suppressor Gene Candidates in Laryngeal Squamous Cell Carcinoma [J].
Giefing, Maciej ;
Zemke, Natalia ;
Brauze, Damian ;
Kostrzewska-Poczekaj, Magdalena ;
Luczak, Magdalena ;
Szaumkessel, Marcin ;
Pelinska, Kinga ;
Kiwerska, Katarzyna ;
Tonnies, Holger ;
Grenman, Reidar ;
Figlerowicz, Marek ;
Siebert, Reiner ;
Szyfter, Krzysztof ;
Jarmuz, Malgorzata .
GENES CHROMOSOMES & CANCER, 2011, 50 (03) :154-166
[10]   Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium [J].
Goebell, Peter J. ;
Knowles, Margaret A. .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2010, 28 (04) :409-428